Neurogenic Detrusor Overactivity Clinical Trials

27 clinical trials for Neurogenic Detrusor Overactivity across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC — RECRUITING · PHASE2
• Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization — RECRUITING · PHASE1
• Improving Pelvic Rehabilitation Using Epidural Stimulation After Spinal Cord Injury — RECRUITING · NA
• A PHASE 2/3, OPEN-LABEL, BASELINE-CONTROLLED, MULTICENTER, LONG-TERM STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF VIBEGRON IN PEDIATRIC SUBJECTS 2 YEARS TO < 18 YEARS OF AGE WITH NEUROGENIC DETRUSOR OVERACTIVITY (NDO) ON CLEAN INTERMITTENT CATHETERIZATION (CIC) — RECRUITING · PHASE2
• A PHASE III, MULTICENTRE, RANDOMISED, DOUBLE BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONE OR MORE INTRADETRUSOR TREATMENTS OF 600 OR 800 UNITS OF DYSPORT FOR THE TREATMENT OF URINARY INCONTINENCE IN SUBJECTS WITH NEUROGENIC DETRUSOR OVERACTIVITY DUE TO SPINAL CORD INJURY OR MULTIPLE SCLEROSIS — RECRUITING · PHASE3
• The aim of the study is to assess the efficacy and safety of intra - detrusor injections of Dysport versus placebo in subjects suffering from neurogenic detrusor overactivity following spinal cord injury or multiple sclerosis. — COMPLETED · PHASE2
• A Phase 2/3, Open-label, Baseline-controlled, Multicenter, Long-term Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age with Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC) — TERMINATED · PHASE3
• A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity — ACTIVE_NOT_RECRUITING · PHASE3
• A Phase 3, Open Label, Multicenter, Baseline-controlled Sequential Dose Titration Study Followed by a Fixed Dose Observation Period to Evaluate Pharmacokinetics, Efficacy and Safety of Mirabegron Prolonged-release Microgranula-based Suspension in Children from 6 Months to Less Than 3 Years of Age with Neurogenic Detrusor Overactivity — OTHER · PHASE3
• Optimization of OnabotulinumtoxinA (BTX-A) Injection for the Treatment of Neurogenic Lower Urinary Tract Dysfunction — COMPLETED · NA
• A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity — COMPLETED · PHASE3
• Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity — COMPLETED · PHASE3
• A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO) — COMPLETED · PHASE3
• A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB) — COMPLETED · PHASE1
• Single Dose Study to Measure Blood Levels and Safety of a Drug for Children With Overactive Bladder — COMPLETED · PHASE1
• A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder — COMPLETED · PHASE1
• Dorsal Genital Nerve Stimulation for Bladder Management After SCI — OTHER · NA
• A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity — TERMINATED · PHASE2
• BIOEQUIVALENCE STUDY IN HEALTHY PARTICIPANTS COMPARING 4 MG AND 8 MG FESOTERODINE EXTENDED-RELEASE TABLETS (TOVIAZ™), MANUFACTURED AT ZWICKAU VERSUS FREIBURG — COMPLETED · PHASE1
• Study To Assess The Bioequivalence Under Fed And Fasted Conditions Of The Fesoterodine Beads-In-Capsule SR4 And SR7 Formulations And To Estimate The Bioavailability of SR7 Beads Sprinkled On Apple Sauce Relative To The Beads-In-Capsule SR7 Formulation Administer — COMPLETED · PHASE1
• Effects of Rec 0/0438 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury — COMPLETED · PHASE1
• Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord Injury — COMPLETED · PHASE1
• Treatment of Neurogenic Detrusor Overactivity: Early Versus Late Pudendal Nerve Stimulation in Spinal Cord Injury (SCI) Patients — WITHDRAWN · NA
• Is the Nerve Growth Factor (NGF) a Useful Biomarker in Neurogenic Bladder Dysfunction After Spinal Cord Injury? — COMPLETED
• Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity — COMPLETED · PHASE4
• Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years — COMPLETED · PHASE2
• Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor Overactivity — COMPLETED · PHASE3

Refine this search